Introduction
============

In contrast to solid organ transplantation, HLA matching is critical in allogeneic hematopoietic stem cell transplantation (HSCT) and ABO incompatibility is not considered a barrier, but it seems that erythrocyte recovery delay and hemolytic complications maybe a problem by the presence of recipient antibodies against donor ABO antigens. The increased risk of hemolytic reactions in ABO incompatible HSCT is well understood.^[@B1]^Theeffect of ABO incompatibility on transplantation such as overall survival (OS), graft-versus-host disease (GVHD), and relapse is still controversial.^[@B2],[@B8]^ ABO incompatibility has three features: major incompatibility, that happens when the recipient with O blood group receives graft from A/B/AB donor, minor incompatibility which occurs when the donor with anti A/B antibodies donates stem cells to a patient with A/B or AB blood group and bidirectional incompatibility is defined when both donor and recipient have anti ABO antibodies. In this study, we evaluated graft outcomes regarding ABO incompatibility which has been a conflicting issue during recent years. If ABO incompatibility deteriorates graft outcomes, choosing the better donor may improve HSCT results, albeit if possible.

SUBJECTS AND METHODS
====================

We prospectively followed the patients (n=501) undergoing allogeneic stem cell transplantation between 2010 and 2012 in our center for a median time of 34.7 months. Patients' characteristics are shown in [Table1](#T1){ref-type="table"}.

###### 

Patients' characteristics

  ---------------------------------------------------------------------------------------------------------------------
                                                        Total     Match     Major\     Minor\     Bidirec-\   P value
                                                                            mismatch   mismatch   tional      
  ------------------------ ---------------------------- --------- --------- ---------- ---------- ----------- ---------
  Recipient age                                                                                               

                           Mean (Median)                24.3\     24.8\     22.9\      25.9\      19.8\       0.034
                                                        (23)      (25)      (19)       (23)       (16)        

                           Range                        1-63      1-57      1-63       1-61       1-54        

  Recipient gender                                                                                            

                           Male                         298       174       55         53         16          0.32

                           Female                       203       117       46         26         14          

  Gender mismatch                                                                                             

                           D-R Sex-Match                245       144       47         40         14          0.422

                           Female to Male               138       73        31         27         7           

                           Male to Female               118       74        23         12         9           

  Conditioning regimen                                                                                        

                           Myeloablative                442       252       92         70         28          0.512

                           Non-myeloablative            59        39        9          9          2           

  ATG in Conditioning                                                                                         

                           Yes                          115       52        32         23         8           0.013

                           No                           385       239       69         55         22          

  HLA type                                                                                                    

                           Full match sibling           475       279       93         76         27          0.23

                           HLA matched other relative   16        6         5          2          3           

                           HLA mismatch relative        10        6         3          1          0           

  Primary diseases                                                                                            

                           Malignant                    318       192       56         52         18          0.268

                           Benign                       183       99        45         27         12          

  Stem cell source                                                                                            

                           PBSC                         456       270       86         72         28          0.223

                           BM                           38        16        14         6          2           

                           CB                           7         5         1          1          0           

  Mononuclear Cell Dose\   Mean\                        8.02\     8.35\     7.20\      8.05\      7.44\       0.26
  \*108/Kg                 (Median)                     (8.04)    (8.04)    (8.03)     (8.07)     (8.02)      

  CD34 cell dose\*106/Kg   Mean\                        4.03\     4.06\     4.01\      3.93\      4.04\       0.68
                           (Median)                     (3.7)     (3.85)    (3.25)     (3.5)      (3.77)      

  CD3 cell dose\*106/Kg    Mean\                        274.04\   275.52\   281.91\    262.79\    262.99\     0.36
                           (Median)                     (284)     (289.5)   (288)      (274)      (260)       
  ---------------------------------------------------------------------------------------------------------------------

PBSC: peripheral Blood Stem Cell, BM: Bone Marrow, CB: Cord Blood,

Malignant diseases (n=318) included acute myeloid leukemia (AML), acute lymphoid leukemia (ALL), chronic myeloid leukemia (CML), myelodysplastic syndrome (MDS), malignant lymphoma and multiple myeloma (MM), while severe aplastic anemia (SAA), thalassemia, Fanconi anemia, osteopetrosis and leukocyteadhesion deficiency syndrome were defined as benign disorders (n=183). Four hundred forty-two patients received myeloablative (MA) conditioning regimen and others (n=59) were transplanted with non-myeloablative regimen.

Stem cell source was peripheral blood in 456 patients and the rest received cells from bone marrow (n=38) and cord blood (n=7). Acute GVHD (aGVHD) grade was determined according to Glucksberg system by presentation and staging of gastrointestinal, liver and skin GVHD at least seven days after transplantation.^[@B9]^Absolute neutrophil count (ANC) more than 0.5 \*109/L for 3 consequent days was considered as neutrophil recovery and platelet engraftment was determined by platelet count of greater than 20\*109/L for three consequent days without any supplementary platelet. Chimerism was assessed on days +15, +30, +60 and +90. Relapse and secondary graft failure were identified by clinical and /or hematologic recurrence or chimerism decline. Death due to treatment except relapse was defined as none-relapse mortality (NRM). Dates of relapse and death were recorded to identify relapse-free survival (RFS) and overall survival (OS). All participants signed the informed consent forms.

**Statistical Analysis**

Statistical analysis was performed using SPSS version 22.0. The incidences of death, relapse, acute and chronic GVHD were compared in each ABO blood group incompatibility using cross-tab tables with likelihood-ratio χ2 statistics. The means of recipient's and donor's age, platelet and WBC engraftment, packed cell and platelet infusion were compared using ANOVA and Kruskal-wallis with post-hoc statistics. Overall survival and relapse-free survival were analyzed by the Kaplan-Meier method, and the Breslow test was used to examinesignificant differences among blood group compatibilities. Factors that significantly affected survival and relapse-free survival were evaluated by the Cox proportional hazards multivariate model. Logistic regression multivariate analysis was used to determine significant effects of variables on incidence of mortality, relapse, and non-relapse mortality, acute and chronic GVHD as outcomes.^[@B10],[@B12]^

Results
=======

According to ABO compatibility of donors and recipients, four groups were distinguished: match, major mismatch, minor mismatch and bidirectional ABO mismatch. Recipient's gender, gender mismatch, conditioning regimen, HLA matching, primary disease, stem cell source, receiving ATG(anti-thymocyte globulin) in conditioning regimen, mononuclear cells, CD34 and CD3 cell doses were almost equally distributed in these four groups. Only recipient's age was different among groups (p-value= 0.034). [Table 1](#T1){ref-type="table"} shows univariate analysis of patients' characteristics.

Univariate analysis of transplantation outcomes regarding BO compatibility groups showed no significant difference inaGVHD, cGVHD, time to neutrophil recovery, NRM and relapse rate in all groups. Chimerism was different among groups, but it was not significant (p-value=0.078).Mean days of platelet engraftment, units of packed cell transfusion, units of platelet infusion and death incidence rate were statistically different ([Table 2](#T2){ref-type="table"}).

Minor and bidirectional mismatched groups received significantly more packed cells than matched group (p- value\<0.0001 and p-value =0.002, respectively). Although major mismatched patients received more packed cells than matched group, the difference was not significant (p value =0.06).The Mean number of platelet units transfused was significantly more in major mismatched recipients than matched group(p-value=0.031). Death rate was less than expected in matched group and it was much more than expected in minor mismatched group([Table2](#T2){ref-type="table"}).

Totally, overall survival was 39.8 months (95% CI: 38.1 -- 41.5). In univariate analysis, mean survival time (OS) was statistically different among groups (p value= 0.017) and the worst result was found in minor mismatched one .Relapse-free survival (RFS) was 45.3 (95% CI: 44.0 -- 46.7) in all patients and it was lower in minor mismatched group, but the difference was not statistically significant (p value=0.30)

In multivariate analysis of overall survival, minor mismatch ABO incompatibility decreased survival (RR: 2.29, CI: 1.47-3.55, p value\<0.0001). Other ABO incompatibilities did not affect survival ([Table 3](#T3){ref-type="table"}, [Figure1-A](#F1){ref-type="fig"}).Malignant diseases decreased OS (RR:2.62,CI:1.66-4.14,p-value\<0.0001).Grade II to IV acute GVHD, both GI and liver deteriorated the outcome(RR:1.80,CI:1.26-2.57,p-value=0.001 and RR:2.70,CI:1.18-6.17,p-value=0.018,respectively),while limited cGVHD improved OS(RR: 0.48,CI: 0.29-0.81, p value=0.006)([Table3](#T3){ref-type="table"}).

###### 

Post- transplantation outcomes by ABO incompatibility

  ------------------------------------------------------------------------------------------------------------------
                                                      Total    Match    Major\     Minor\     Bidirec-\   P value
                                                                        mismatch   mismatch   tional      
  ---------------------------------------- ---------- -------- -------- ---------- ---------- ----------- ----------
  AGVHD Grade ≥ II                                                                                        

                                           Yes        212      112      47         37         16          0.190

                                           No         274      171      49         40         14          

  CGVHD                                                                                                   

                                           Yes        189      105      37         32         15          0.46

                                           No         312      186      64         47         15          

  Chimerism                                                                                               

                                           \> 95%     442      257      92         64         29          0.078

                                           \< 95%     59       34       9          15         1           

  Neutrophil recovery (+Days)                                                                             

                                           Mean\      14.02\   13.59\   14.98\     13.95\     15.23\      0.64
                                           (Median)   (13)     (13)     (13)       (13)       (13)        

                                           Range      1-66     3-27     9-66       8-44       1-51        

  Plt engraftment (+Days)                                                                                 

                                           Mean\      17.97\   17.15\   19.78\     18.66\     18.07\      0.04
                                           (Median)   (16)     (15)     (17)       (16)       (15)        

                                           Range      4-101    4-101    10-71      8-69       10-38       

  Packed Cell infusion (Unit)              Mean\      2.48\    1.83\    2.89\      3.85\      3.80\       \<0.0001
                                           (Median)   (1)      (1)      (1)        (3)        (4)         

  Platelet infusion (Unit)                 Mean\      4.42\    3.51\    6.18\      5.18\      5.43\       0.002
                                           (Median)   (2)      (2)      (2)        (2)        (3)         

  Relapse[1](#TFN1){ref-type="table-fn"}                                                                  

                                           Yes        75       44       12         16         3           0.38

                                           No         426      247      89         63         27          

  Death[1](#TFN1){ref-type="table-fn"}                                                                    

                                           Yes        139      68       30         31         10          0.034

  \`                                       No         362      223      71         48         20          

  Non-Relapse Mortality                                                                                   

                                           NRM        73       32       18         15         8           0.193

                                           RM         66       36       12         16         2           
  ------------------------------------------------------------------------------------------------------------------

Medianfollow-up: 34.72 months (33.26 -- 36.18)

![Overall Survival by ABO incompatibility Groups in multivariate Cox regression analysis](IJHOSCR-11-139-g001){#F1}

###### 

Multivariate analysis for overall survival and relapse-free survival

  Factors                Overall Survival         Relapse-Free Survival                            
  ---------------------- ------------------------ ----------------------- ------------------------ ----------
                         Relative Risk (95% CI)   P value                 Relative Risk (95% CI)   P value
  ABO compatibility                                                                                
  Match                  1.0                                              1.0                      
  Major mismatch         1.24 (0.77-1.99)         0.38                    0.84 (0.42-1.67)         0.61
  Minor mismatch         2.29 (1.47-3.55)         \<0.0001                1.78 (0.98-3.26)         0.59
  Bidirectional          1.37 (0.65-2.88)         0.41                    0.87 (0.26-2.93)         0.82
  ATG                                                                                              
  Yes                    1.0                                              1.0                      
  No                     0.81 (0.68-3.08)         0.63                    0.31 (0.03-3.04)         0.31
  Primary Disorder                                                                                 
  Benign                 1.0                                              1.0                      
  Malignant              2.62 (1.66-4.14)         \<0.0001                20.5 (6.3-66.9)          \<0.0001
  Recipient Age          1.007 (0.988-1.027)      0.45                    1.001 (0.975-1.027)      0.96
  Donor Age              0.998 (0.979-1.017)      0.81                    0.971 (0.953-0.989)      0.002
  AGVHD Grade ≥ II       0.40 (0.14-1.12)         0.08                    0.77 (0.14-4.21)         0.76
  Skin                   0.63 (0.18-2.19)         0.47                    N/A                      
  GI                     1.80 (1.26-2.57)         0.001                   1.52 (0.28-8.11)         0.62
  Liver                  2.70 (1.18-6.17)         0.018                   0.78 (0.16-3.83)         0.76
  Chronic GVHD           0.77 (0.48-1.25)         0.29                    0.53 (0.31-0.89)         0.02
  No                     1.0                                              1.0                      
  Limited                0.48 (0.29-0.81)         0.006                   0.73 (0.40-1.33)         0.30
  Extensive              0.94 (0.60-1.47)         0.79                    0.23 (0.09-0.63)         0.004
  CD34 Cell dose         1.010 (0.925-1.103)      0.82                    1.123 (0.995-1.267)      0.06
  Conditioning Regimen                                                                             
  Non-MA                 1.0                                              1.0                      
  MA                     1.67 (0.85-3.26)         0.13                    2.41 (0.74-7.87)         0.14
  Gender Mismatch                                                                                  
  D-R Sex-Match          1.0                                              1.0                      
  Female to Male         1.42 (0.93-2.19)         0.10                    1.30 (0.72-2.34)         0.37
  Male to Female         1.13 (0.70-1.79)         0.61                    0.84 (0.44-1.59)         0.59
  HLA Matching                                                                                     
  Sibling                1.0                                                                       
  Match other relative   2.05 (0.64-6.59)         0.23                    N/A                      
  Mismatch relative      1.46 (0.31-6.74)         0.62                    8.12 (0.84-78.4)         0.07
  ANC recovery           1.030 (0.983-1.079)      0.21                    1.057 (0.95-1.175)       0.31
  Plt recovery           0.995 (0.964-1.026)      0.73                    0.985 (0.938-1.033)      0.52

[Table 3](#T3){ref-type="table"} also includes Cox regression multivariate analysis results for RFS. ABO incompatibility was not correlated with RFS ([Figure 1-B](#F2){ref-type="fig"}). Malignant disease decreased RFS (RR: 20.5, CI: 6.3-66.9, p-value\<0.0001). In contrast,donor's age and extensive cGVHD improved RFS (RR: 0.971, CI: 0.953-0.989, p- value=0.002 and RR: 0.23, CI: 0.09-0.63, p- value=0.004, respectively).

![Relapse-Free Survival by ABO incompatibility Groups in multivariate Cox regression analysis](IJHOSCR-11-139-g002){#F2}

The cumulative incidence of relapse was not significantly different among the four groups ([Figure1-C](#F3){ref-type="fig"}).Malignant primary disorder increased relapse rate(RR:31.39, CI: 8.33-118.26,p-value\<0.0001).

![Cumulative incidence probability of Relapse by ABO incompatibility groups](IJHOSCR-11-139-g003){#F3}

Extensive cGVHD and donor's age decreased relapse rate(RR: 0.24, CI: 0.09-0.65,p-value=0.005 and RR:0.970, CI: 0.950-0.991, p-value=0.005, respectively).Donation from a mismatched relative was a risk factor for relapse (RR: 12.39, CI: 1.10-140.32, p-value=0.04) ([Table4](#T4){ref-type="table"}).

###### 

multivariate analysis for Relapse and Non-Relapse Mortality

  Factors                Relapse                  Non-Relapse Mortality                            
  ---------------------- ------------------------ ----------------------- ------------------------ ----------
                         Relative Risk (95% CI)   P value                 Relative Risk (95% CI)   P value
  ABO compatibility                                                                                
  Match                  1.0                                              1.0                      
  Major mismatch         0.71 (0.31-1.60)         0.41                    1.18 (0.52-2.65)         0.70
  Minor mismatch         1.47 (0.67-3.22)         0.33                    1.65 (0.71-3.84)         0.24
  Bidirectional          0.80 (0.20-3.20)         0.75                    1.89 (0.56-6.43)         0.31
  ATG                                                                                              
  Yes                    1.0                                              1.0                      
  No                     0.24 (0.02-3.60)         0.30                    0.86 (0.29-2.52)         0.78
  Primary Disorder                                                                                 
  Benign                 1.0                                              1.0                      
  Malignant              31.39 (8.33-118.26)      \<0.0001                1.04 (0.33-3.29)         0.95
  Recipient Age          1.001 (0.970-1.033)      0.96                    1.019 (0.986-1.053)      0.26
  Donor Age              0.970 (0.950-0.991)      0.005                   1.024 (1.005-1.044)      0.02
  AGVHD Grade ≥ II       0.68 (0.11-4.33)         0.69                    0.25 (0.04-1.66)         0.15
  Skin                   N/A                                              1.72 (0.30-9.76)         0.54
  GI                     1.73 (0.28-10.59)        0.56                    3.32 (1.84-6.00)         \<0.0001
  Liver                  0.55 (0.09-3.28)         0.51                    1.86 (0.50-6.98)         0.36
  Chronic GVHD           0.21 (0.07-0.62)         0.004                   2.26 (1.11-4.60)         0.02
  No                     1.0                                              1.0                      
  Limited                0.80 (0.40-1.60)         0.52                    0.40 (0.16-1.01)         0.05
  Extensive              0.24 (0.09-0.65)         0.005                   2.49 (1.31-4.72)         0.005
  CD34 Cell dose         1.12 (0.98-1.30)         0.11                    0.97 (0.83-1.14)         0.72
  Conditioning Regimen                                                                             
  Non-MA                 1.0                                              1.0                      
  MA                     2.70 (0.77-9.47)         0.12                    1.31 (0.50-3.44)         0.59
  Gender Mismatch                                                                                  
  D-R Sex-Match          1.0                                              1.0                      
  Female to Male         1.36 (0.68-2.74)         0.39                    1.81 (0.86-3.82)         0.12
  Male to Female         0.79 (0.37-1.68)         0.54                    1.63 (0.75-3.54)         0.22
  HLA Matching                                                                                     
  Sibling                1.0                                              1.0                      
  Match other relative   N/A                                              2.90 (0.52-16.18)        0.23
  Mismatch relative      12.39 (1.10-140.32)      0.04                    0.73 (0.6-8.25)          0.80
  ANC recovery           1.02 (0.90-1.16)         0.71                    1.02 (0.94-1.11)         0.61
  Plt recovery           0.97 (0.92-10.3)         0.38                    0.99 (0.93-1.05)         0.68

Multivariate analysis of NRM revealed nodifference among ABO incompatibility groups .Donor's age weakly increased NRM rate (RR: 1.024, CI: 1.005-1.044, p-value=0.02). Acute GI, GVHD and cGVHD were risk factors for increasing NRM rate (RR: 3.32, CI: 1.84-6.00, p-value\<0.0001 and RR: 2.26, CI: 1.11-4.60, p-value=0.02, respectively). While extensive cGVHD significantly increased NRM (RR: 2.49, CI: 1.31-4.72, p-value=0.005), limited cGVHD decreased that rate, but it was not significant (RR: 0.40, CI: 0.16-1.01, p-value=0.05) ([Table 4](#T4){ref-type="table"}, [Figure1-D](#F4){ref-type="fig"}).

![Cumulative incidence probability of NRM by ABO incompatibility groups](IJHOSCR-11-139-g004){#F4}

Multivariate analysis of acute and chronic GVHD showed that MA regimen increased aGVHD(RR: 1.81, CI: 1.003-3.27, p-value=0.049).Omitting ATG (Antithymocyte) from conditioning regimen increased cGVHD (RR: 2.28, CI: 1.35-3.83, p- value=0.002). Both donor's age and aGVHDgrade≥II were risk factors for cGVHD(RR: 1.014, CI: 1.001-1.027, p-value=0.04 and RR: 1.49, CI: 1.02-2.20, p-value=0.04) and also female to male donation increased cGVHD(RR: 2.01, CI: 1.28-3.16, p-value=0.002)

Pure red cell aplasia (PRCA) occurred in two male patients (with ALL and SAA) in major mismatched group; one of whom had received cells from female and the other from male HLA - identical sibling donor.They received MA and non-MA regimen as conditioning, respectively.aGVHDof liver (grade II-III) and also cGVHD were presented in both patients.

Discussion
==========

Approximately one-third of bone marrow or peripheral blood stem cell transplantations are performed with ABO blood group incompatibility.^[@B2],[@B13]^

In this study, we evaluated the impact of ABO mismatch on outcomes such as OS, RFS, and NRM, time to engraftment, relapse and also GVHD**.** A decrease in OS was only observed in patients undergoing minor blood group mismatched HCT.

We observed that a decrease in OS occurred only in patients with minor blood group mismatched transplantations. RFS was lower in minor mismatched grafts, but the difference was not statistically significant. Similar to our results, Ozkurt et al.'s and Logan et al.'s studies also reported a significantly shorter OS in recipients with minor ABO-mismatched grafts.^[@B14],[@B15]^Stussi et al. observed an independent decrease in survival after bidirectional ABO-incompatible SCT, but it was not found in the minor or major ABO-incompatible groups.^[@B2]^Three hundred thirty-eight patients with ABO-incompatible SCT were evaluated by Mielcarek et al., and there were no significant differences in survival and GVHD among the ABO-incompatible groups.^[@B3]^Some other studies have also reported no relationship between ABO groups and OS.^[@B3],[@B5],[@B6],[@B16]^In a large retrospective study conducted in Japan, OS was significantly lower in major and minor mismatched groups than the AB0-identical group.^[@B17]^Time to ANC engraftment was not different among study groups. This result was confirmed in Mielcarek et al.'s and Kim et al.'sstudies.^[@B3],[@B6]^We observed significant difference in mean platelet engraftment time among four groups and major mismatched group showed the maximum platelet engraftment time. Japanese study showed engraftment delay in neutrophils, platelets, and erythrocytes in transplants with major incompatibility.^[@B17]^

Minor and bidirectional mismatched groups required more packed cell infusion than matched group. Major mismatches received more platelet infusion than others. Although Ozkurt et al. and Kim et al. studies have shown that ABO-mismatched groups had no greater transfusion requirements than ABO-identical ones,^[@B6],[@B14]^ some other studies have shown that ABO-incompatible group has greater transfusion requirements.^[@B3],[@B5]^

Similar to Seebach et al. study,^[@B16]^ we observed no difference in relapse and NRM between ABO-pairs. But Kimura et al. showed higher NRM in the major and minor mismatched groups. Meanwhile, just like our results,they did not find any significant difference in rate of relapse.^[@B16]^In 2015, Biology of Blood and Marrow Transplantation Journal published an article reporting an increase in NRM of minor mismatched groups.^[@B15]^

Some studies that ABO incompatibility may be associated with increased risk of GVHD.^[@B17]-[@B19]^ In one report, minor ABO incompatibility was related with a higher risk of severe acute GVHD in comparison to other groups,^[@B20]^ but in our study, aGVHD and cGVHD were not statistically correlated with ABO compatibility. Mielcarek et al. and also Kim et al. have also reported similar results.^[@B3],[@B6]^

Pure red cell aplasia (PRCA) occurred in two male patients (with ALL and SAA) of our major mismatched group. They received transplantation from female and male HLA - identical sibling donors, respectively. PRCA has also been reported after major ABO-incompatible stem cell transplantation in other studies.^[@B2],[@B21],[@B22]^ Finally, in our study, multivariate analysis revealed that MA regimen increased aGVHD and omitting ATG, donor'sage,aGVHD≥II and female to male donation were all risk factors for developing cGVHD.

Since unfavorable outcomes and complications such as decrease in OS, the need for more transfusion and PRCA are statistically significant in ABO incompatible SCT, we suggest that in clinical practice, if a given patient has several suitable donors, the one with a compatible ABO blood group would improve outcomes of the transplantation.

Considering relatively diverse results on this topic in the literature, a study with a larger sample size and also a meta-analysis could probably help achieve more accurate results.

CONCLUSION
==========

Since unfavorable outcomes such as decrease in OS and the need for more transfusions are statistically significant in ABO incompatible SCT and also complicationsuch as PRCA is observed in these patients, we suggest that in clinical practice, if a given patient has several suitable donors, the one with a compatible ABO blood group would improve outcomes of the transplantation.

Considering relatively diverse results on this topic in the literature, a study with a larger sample size and also a meta-analysis could probably help achieve more accurate results.
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